Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

French study to track endoscopic surgery for early esophageal cancer in 750 patients

NCT ID NCT07343869

Knowledge-focused Sponsor: Société Française d'Endoscopie Digestive Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 750 adults in France who undergo endoscopic submucosal dissection (ESD) for early esophageal cancer or precancerous Barrett's esophagus. Researchers will track how well the procedure removes the cancer, how often it comes back, and whether additional treatments like surgery or chemotherapy improve outcomes. The goal is to provide real-world evidence to guide treatment decisions for this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
endoscopic submucosal dissection (ESD)
What this could lead to
If successful, this study could help doctors better predict which patients need additional treatment after ESD, improving personalized care for early esophageal cancer.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove what works best. Results may vary across hospitals and patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 750 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Feb 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible patients include all individuals referred to a participating center for endoscopic resection of an esophageal lesion and treated by submucosal dissection. This is a prospective, multicenter, observational study, conducted on an intention-to-treat basis. All consecutive patients referred for esophageal ESD will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥ 18 years old) * Patients referred for endoscopic resection of an esophageal lesion and treated by submucosal dissection * Patients managed in one of the participating centers * Patient who has received oral and written information about the study and has not objected to participation * Patients covered by a social security or health insurance scheme. Exclusion Criteria: * Patient refusal after reading the information sheet * Patient under legal protection (guardianship, curatorship, court-ordered protection) * Inability to inform the patient due to cognitive impairment, language barrier, or medical emergency * Patients previously included for another lesion in the same study * Pregnant or breastfeeding women. * Patient deprived of liberty. * Patient currently enrolled in another clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Barretts esophagus with dysplasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus Barrett esophagus esophageal adenocarcinoma esophageal squamous cell carcinoma esophagus carcinoma in situ

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Barretts esophagus with dysplasia Oesophageal adenocarcinoma Oesophageal squamous cell carcinoma Superficial esophageal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jules Verne Clinic

    Nantes, 44300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.